Evidence map›Paper›PMID 42489032›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

Modularized GSH-Proton Tandem-Responsive "Off-Brighter" Persistent Luminescent Nano-System for Visualized Synergetic PTT & CDT of Mastocarcinoma.

Chang Yin, Kai Long, Xinxin Yuan, Pengfei Lu, Wei Wang, Zhi Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chang YinKey Laboratory of Functional Polymer Materials of the Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, China.
Kai LongKey Laboratory of Functional Polymer Materials of the Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, China.
Xinxin YuanKey Laboratory of Functional Polymer Materials of the Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, China.
Pengfei LuKey Laboratory of Functional Polymer Materials of the Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, China.
Wei WangKey Laboratory of Functional Polymer Materials of the Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, China.
Zhi YuanKey Laboratory of Functional Polymer Materials of the Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin, China.

Funding

National Natural Science Foundation of China 52073147
6 · The paper itself

Abstract

Visualized theranostics is a powerful tool for guiding cancer diagnosis, therapy, and prognosis through medical imaging; nevertheless, simultaneously achieving high imaging contrast, reliable therapeutic efficacy, inter-component cooperativity, and broad methodological versatility with a facile strategy remains exceedingly challenging. For the first time, this study introduces a novel modular "Off-Brighter" persistent luminescence (PersL) theranostic strategy for visualized cancer therapy. The nano-agent integrates two functional modules: a proton-responsive PersL imaging brick (ZR) optimized via dye-sensitization, and a GSH-responsive synergistic photothermal/chemodynamic therapy brick (PAHIR-Fcss) loaded with IR808 and FcSH. FcSH temporarily quenches ZR's PersL, creating "GSH-proton" tandem-responsive "Off-Brighter" activation that enhances luminescence 12.3-fold and achieves tumor imaging contrast of 274.95. Real-time imaging guided drug delivery monitoring, identifying the 3rd h post-injection as optimal for combination therapy. The synergistic photothermal/chemodynamic approach attained 96.2% tumor suppression in murine breast cancer models. Subsequent PersL imaging-based assessment determined that a single 14-day treatment course optimizes efficacy while preventing overtreatment risks. The modular design enables free exchange of imaging and therapeutic components, offering a versatile, generalizable platform for tailored clinical applications.

Indexed as

GlutathioneNanoparticlesPhototherapyPhotothermal TherapyProtonsAnimalsCell Line, TumorFemaleHumansLuminescenceMiceGlutathioneProtonsmodularizationpersistent luminescencePTT/CDT synergytumor therapy visualization

Identifiers

PMID42489032
PMCPMC13580302

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.